Natera, Inc. $NTRA Shares Acquired by Swedbank AB

Swedbank AB grew its stake in Natera, Inc. (NASDAQ:NTRA) by 6.7% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 48,184 shares of the medical research company’s stock after acquiring an additional 3,014 shares during the quarter. Swedbank AB’s holdings in Natera were worth $11,038,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also modified their holdings of the stock. SBI Securities Co. Ltd. increased its stake in shares of Natera by 15.9% in the 4th quarter. SBI Securities Co. Ltd. now owns 502 shares of the medical research company’s stock worth $115,000 after acquiring an additional 69 shares during the last quarter. Alpha Cubed Investments LLC acquired a new stake in shares of Natera in the 4th quarter worth $206,000. Morse Asset Management Inc acquired a new stake in shares of Natera in the 4th quarter worth $402,000. QRG Capital Management Inc. increased its stake in shares of Natera by 168.9% in the 4th quarter. QRG Capital Management Inc. now owns 12,507 shares of the medical research company’s stock worth $2,865,000 after acquiring an additional 7,855 shares during the last quarter. Finally, Pinnacle Wealth Management Advisory Group LLC acquired a new stake in shares of Natera in the 4th quarter worth $485,000. 99.90% of the stock is owned by institutional investors and hedge funds.

Natera News Summary

Here are the key news stories impacting Natera this week:

• Positive Sentiment: JPMorgan raised its price target on Natera to $265 from $260 and kept an overweight rating, signaling confidence in further upside from current levels. JPMorgan raises Natera price target
• Positive Sentiment: Wells Fargo also lifted its target to $220 from $215, indicating continued analyst support despite a more neutral equal-weight stance. Wells Fargo raises Natera price target
• Positive Sentiment: First-quarter revenue came in well above expectations at $696.6 million, up 38.8% year over year, and the company also reported gross margin of 64.7%, showing strong top-line growth. Natera Q1 results
• Neutral Sentiment: Natera updated full-year 2026 revenue guidance to $2.7 billion-$2.8 billion, roughly in line with consensus, which suggests the outlook is steady but not a major surprise. Natera guidance update
• Negative Sentiment: Profitability remains a concern: Natera posted a quarterly loss of $0.60 per share, wider than the expected $0.53 loss, despite the revenue beat. Natera earnings miss
• Negative Sentiment: Recent insider selling, including a CEO stock sale, may add pressure by reinforcing concerns about valuation after the stock’s strong run. Natera CEO stock sale

Insiders Place Their Bets

In other news, CEO Steven Leonard Chapman sold 5,838 shares of the stock in a transaction on Monday, April 27th. The stock was sold at an average price of $204.14, for a total transaction of $1,191,769.32. Following the completion of the transaction, the chief executive officer directly owned 150,769 shares in the company, valued at approximately $30,777,983.66. This represents a 3.73% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Solomon Moshkevich sold 3,405 shares of the stock in a transaction on Friday, May 1st. The stock was sold at an average price of $203.69, for a total value of $693,564.45. Following the transaction, the insider owned 142,295 shares of the company’s stock, valued at approximately $28,984,068.55. This represents a 2.34% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last quarter, insiders have sold 38,266 shares of company stock valued at $7,747,808. 5.63% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

A number of analysts have issued reports on NTRA shares. Robert W. Baird set a $265.00 target price on Natera in a research note on Friday. Canaccord Genuity Group reaffirmed a “buy” rating on shares of Natera in a research note on Monday, January 12th. Wells Fargo & Company raised their target price on Natera from $215.00 to $220.00 and gave the stock an “equal weight” rating in a research note on Friday. William Blair started coverage on Natera in a research note on Tuesday, April 14th. They issued an “outperform” rating for the company. Finally, JPMorgan Chase & Co. raised their target price on Natera from $260.00 to $265.00 and gave the stock an “overweight” rating in a research note on Friday. One equities research analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $256.00.

Natera Trading Down 11.6%

NASDAQ NTRA opened at $194.24 on Friday. The stock has a market cap of $27.64 billion, a PE ratio of -119.17 and a beta of 1.57. Natera, Inc. has a twelve month low of $131.81 and a twelve month high of $256.36. The stock has a fifty day simple moving average of $202.23 and a 200-day simple moving average of $215.02.

Natera (NASDAQ:NTRA) last released its quarterly earnings results on Thursday, February 26th. The medical research company reported $0.35 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.46) by $0.81. The business had revenue of $665.50 million during the quarter, compared to analysts’ expectations of $600.68 million. Natera had a negative return on equity of 15.72% and a negative net margin of 9.05%.During the same period in the prior year, the business posted ($0.41) EPS. Research analysts predict that Natera, Inc. will post -1.71 EPS for the current year.

Natera Company Profile

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.